QIAGEN N.V. announces successful completion of non-U.S. offer involving convertible notes

Ad-hoc announcement pursuant to Art. 17 MAR

QIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 (MAR) and the Delegated EU Regulation 2016/1052 / Share Repurchase

QIAGEN reports results for second quarter and first half of 2017

DiaSorin and QIAGEN sign collaboration to expand liaison test menu through adoption of select QIAGEN assays

French health-system approves reimbursement of QIAGEN's QuantiFERON latent TB test 

QIAGEN's QuantiFERON®-TB Gold Plus gains U.S. FDA approval

QIAGEN receives U.S. FDA approval for cytomegalovirus (CMV) testing on automated QIAsymphony platform 

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies